Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice

Molecular Therapy

Volumn 8, Issue 3, 2003, Pages 434-440

  Huang, Tian Gui ^a   Ebert, Oliver ^a   Shinozaki, Katsunori ^a   García Sastre, Adolfo ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer gene therapy; Metastatic colorectal carcinoma; Oncolytic virus; Vesicular stomatitis virus

Indexed keywords

GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS; VIRUS ANTIBODY; VIRUS ONCOLYSATE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; HOST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IN VITRO STUDY; ISOGRAFT; LIVER CELL; LIVER METASTASIS; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; RNA VIRUS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR NECROSIS; VESICULAR STOMATITIS VIRUS; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALIA; MURINAE; RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 0141744727     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00204-1     Document Type: Article

References (36)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. (2002). Cancer statistics, 2002. CA Cancer J. Clin. 52: 23-47.
2. Saltz, L. B., et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N. Engl. J. 343: 905-914.
3. Lorenz, M., and Muller, H. H. (2000). Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J. Clin. Oncol. 18: 243-254.
4. Letchworth, G. J., Rodriguez, L. L., Del, C., and Barrera, J. (1999). Vesicular stomatitis. Vet. J. 157: 239-260.
5. Stojdl, D. F., et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6: 821-825.
6. Kim, D., Martuza, R. L., and Zwiebel, J. (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7: 781-787.
7. Stojdl, D. F., et al. (2000). The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J. Virol. 74: 9580-9585.
8. Williams, B. R. (1999). PKR: A sentinel kinase for cellular stress. Oncogene 18: 6112-6120.
9. Bergmann, et al. (2001). A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res. 61: 8188-8193.
10. Farassati, F., Yang, A. D., and Lee, P. W. (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3: 745-750.
11. Lorence, R. M., et al. (1994). Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 54: 6017-6021.
12. Coffey, M. C., Strong, J. E., Forsyth, P. A., and Lee, P. W. (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
13. Lawson, N. D., Stillman, E. A., Whitt, M. A., and Rose, J. K. (1995). Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA 92: 4477-4481.
14. Whelan, S. P., Ball, L. A., Barr, J. N., and Wertz, G. T. (1995). Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. USA 92: 8388-8392.
15. Boritz, E., Gerlach, J., Johnson, J. E., and Rose, J. K. (1999). Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: Entry by a pH-independent pathway. J. Virol. 73: 6937-6945.
16. Ebert, O., Shinozaki, K., Huang, T. G., Savontaus, M. J., Garcia-Sastre, A., Woo, S. L. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. (in press).2003.
17. Chen, S. H., et al. (1995). Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA 92: 2577-2581.
18. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856.
19. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1: 938-943.
20. Miyatake, S. I., et al. (1999). Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 6: 564-572.
21. Whitley, R. J., Kern, E. R., Chatterjee, S., Chou, J., and Roizman, B. (1993). Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J. Clin. Invest. 91: 2837-2843.
22. Mineta, T., Markert, J. M., Takamiya, Y., Coen, D. M., Rabkin, S. D., and Martuza, R. L. (1994). CNS tumor therapy by attenuated herpes simplex viruses. Gene Ther. 1(Suppl. 1): S78.
23. Barker, D. D., and Berk, A. J. (1987). Adenovirus proteins from both E1 B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156: 107-121.
24. Bischoff, J. R., et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.. Science 274: 373-376.
25. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. (1977). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3: 639-645.
26. Fueyo, J., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12.
27. Hallenbeck, P. L., et al. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma.. Hum. Gene Ther. 10: 1721-1733.
28. Wickham, T. J., et al. (1997). Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71: 8221-8229.
29. Alemany, R., Balague, C., and Curiel, D. T. (2000). Replicative adenoviruses for cancer therapy.. Nat. Biotechnol 18: 723-727.
30. Chen, S. H., et al. (1996). Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival. Cancer Res. 56: 3758-3762.
31. Caruso, M., et al. (1996). Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA 93: 11302-11306.
32. Chen, S. H., et al. (2000). Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2: 39-46.
33. Martinet, O., et al. (2000). Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model. J. Natl. Cancer Inst. 92: 931-936.
34. Pan, P. Y., Zang, Y., Weber, K., Meseck, M. L., and Chen, S. H. (2002). OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 6: 528-536.
35. Balachandran, S., Porosnicu, M., and Barber, G. N. (2001). Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol. 75: 3474-3479.
36. Fernandez, M., Porosnicu, M., Markovic, D., and Barber, G. N. (2002). Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J. Virol. 76: 895-904.